Tc-99m MDP Bone Scintigraphy: Technique and QC

The Tc-99m MDP bone scan is the cornerstone of skeletal nuclear medicine, and its diagnostic power is built entirely on physics that the technologist and physicist control. Chemisorption of diphosphonate onto bone mineral, a 140 keV photon matched to the gamma camera, delayed imaging that clears soft tissue, and SPECT/CT that converts a hot spot into an anatomic diagnosis—each step has acquisition parameters and QC behind it. ¹²

This guide walks through the radiopharmaceutical, the three-phase technique, the acquisition physics, dosimetry, and the SPECT/CT workflow, then connects each to the quality-control practices that keep the study reliable and defensible.

Introduction

Bone scintigraphy is a highly sensitive functional imaging technique that maps active bone formation across the whole skeleton in a single study. It detects the metabolic response to malignant and benign disease and to physiologic remodeling, often earlier than the anatomic changes visible on radiographs. ¹

The tracer, Tc-99m bound to a diphosphonate, accumulates wherever osteoblastic activity and regional blood flow are elevated. That functional mechanism is the study's great strength—high sensitivity—and its limitation—modest specificity, since many different processes raise bone turnover. The modern answer to the specificity problem is hybrid imaging: SPECT/CT that localizes and characterizes the finding. ¹⁶

For a facility, a reliable bone-scan service depends on getting the physics right: correct radiopharmaceutical preparation, appropriate administered activity, correct collimator and energy window, adequate delay, sufficient counts, and validated SPECT/CT calibration. DRPS supports these programs through PET/CT and nuclear medicine physics services.

Topic Explanation

The radiopharmaceutical

Technetium-99m is the dominant diagnostic radionuclide in nuclear medicine because its 140 keV gamma photon is efficiently detected by a sodium iodide gamma camera and its 6-hour physical half-life balances image counts against patient dose. For skeletal imaging, Tc-99m is chelated to a diphosphonate—most often methylene diphosphonate (MDP) or hydroxymethylene diphosphonate (HDP/HMDP). ¹²

Once injected, the diphosphonate distributes through the vascular space and undergoes chemisorption onto the hydroxyapatite crystal surface of bone mineral. The magnitude of uptake in any region reflects the local rate of bone turnover and osteoblastic activity, modulated by regional blood flow. Pathologies that increase these—metastasis, fracture, infection, arthropathy, Paget disease—appear as foci of increased accumulation. ¹

Why imaging is delayed

Immediately after injection, much of the tracer is still in the blood and soft tissues, producing high background that obscures bone. Over the next few hours, the unbound fraction clears—predominantly by renal excretion—while the bone-bound fraction is retained. Delaying imaging therefore raises the bone-to-background ratio and lesion conspicuity. Guidelines specify a delay of roughly 2 to 5 hours, with hydration and voiding before imaging to further reduce soft-tissue and bladder activity. ¹²

The three-phase study

When infection or an acute process is the clinical question, a three-phase acquisition is used:

• Flow (perfusion) phase — rapid dynamic frames during and immediately after bolus injection, showing regional arterial blood flow.
• Blood-pool (soft-tissue) phase — static images within minutes of injection, reflecting hyperemia and extracellular distribution.
• Delayed (bone) phase — images at 2 to 5 hours, reflecting osteoblastic uptake.

Comparing the phases separates hyperemic, metabolically active processes (osteomyelitis, acute fracture, complex regional pain) from findings that are only positive on the delayed phase. ¹²

Key Technical Principles

The three phases at a glance

All phases use a low-energy high-resolution (LEHR) parallel-hole collimator and a photopeak energy window centered on 140 keV (commonly 15–20% wide). The collimator sets the fundamental trade-off between spatial resolution and sensitivity; the delayed phase, where fine lesion detection matters most, is where LEHR resolution is most valuable. For how that choice is made, see gamma camera collimator selection. ¹²

Worked example: effective dose

Effective dose scales linearly with administered activity through the radiopharmaceutical's dose coefficient. For Tc-99m diphosphonate, ICRP Publication 128 gives an adult effective-dose coefficient of approximately $e=0.0057$ mSv/MBq. For a typical adult administered activity $A=740$ MBq (20 mCi):

$$E=A\times e=740\text{MBq}\times 0.0057\frac{\text{mSv}}{\text{MBq}}\approx 4.2\text{mSv}$$

At the upper end of the usual range, $A=1110$ MBq (30 mCi):

$$E=1110\text{MBq}\times 0.0057\frac{\text{mSv}}{\text{MBq}}\approx 6.3\text{mSv}$$

This places a routine bone scan in the low-single-digit to ~6 mSv range, comparable to other common nuclear medicine and CT studies. Because dose scales with activity, administering the lowest activity that yields adequate counts is the primary patient-dose lever. ⁷

Worked example: physical decay and imaging delay

Tc-99m decays with physical half-life $T_{1/2}=6.0$ h and decay constant $\lambda =\ln 2/T_{1/2}$. The remaining activity at delay time $t$ is:

$$A(t)=A_0{e}^{-\lambda t}=A_0{e}^{-\frac{\ln 2}{T_{1/2}}t}$$

At a 3-hour delay:

$$\frac{A(3\text{h})}{A_0}=e^{-\frac{0.693}{6.0}\times 3}=e^{-0.347}\approx 0.71$$

So about 71% of the injected activity remains physically at 3 hours. The reason the delayed image looks better than an early image is not more counts—it is fewer background counts: soft-tissue clearance raises the target-to-background ratio even as total activity falls. This is why count density (acquisition time or count target), not just delay, must be specified so the delayed image is statistically adequate. ¹²

SPECT and SPECT/CT

Planar whole-body imaging is sensitive but flattens three-dimensional anatomy into two dimensions, producing overlap and equivocal reads. SPECT recovers depth; the co-registered CT supplies anatomic correlation and attenuation context. Together they characterize a planar hot spot—facet arthropathy versus vertebral metastasis, a healing rib versus a lytic lesion. A comparative study of solitary skeletal lesions reported diagnostic accuracy rising from about 67% for SPECT alone and 83% for CT alone to roughly 86% for SPECT/CT, with markedly fewer equivocal lesions. ⁶ Quantitative SPECT/CT extends this further toward reproducible uptake metrics; see quantitative SPECT/CT calibration and SPECT/CT quality control. ⁵

Clinical Impact

Bone scintigraphy earns its place by surveying the entire skeleton in one sensitive study, but its value in any individual case depends on technique and QC. ¹⁶

In oncology, the whole-body bone scan screens for skeletal metastases in prostate, breast, and other cancers, guiding staging and therapy decisions. In benign disease, it localizes occult fractures, stress injuries, osteomyelitis, prosthesis loosening or infection, and metabolic bone disease. The three-phase protocol is central to the infection and complex-regional-pain questions, where the early hyperemic phases carry the discriminating information. ¹²

The recurring pitfall is specificity. A single planar hot spot is often indeterminate, and reading it in isolation invites both false-positive alarm and false-negative reassurance. The technical remedies are consistent: adequate delay and hydration for contrast, sufficient counts for statistical reliability, and SPECT/CT for anatomic characterization of equivocal findings. A facility that under-counts its delayed images or skips SPECT/CT on indeterminate lesions is trading away the study's real-world accuracy. ¹⁶ Newer full-ring CZT SPECT/CT systems are changing acquisition workflows and may reduce reliance on planar whole-body imaging, but the same physics of counts, resolution, and localization governs image quality. ⁴

Interpretation also depends on recognizing physics-driven patterns that mimic or mask disease. A superscan occurs when diffuse, intense skeletal uptake from widespread metastatic or metabolic disease suppresses the renal and soft-tissue background so completely that the scan can be misread as normal—faint or absent kidney visualization is the clue. The flare phenomenon is a transient apparent worsening of uptake in healing metastases responding to therapy, reflecting an osteoblastic repair response rather than progression; distinguishing it from true progression requires knowing the treatment timeline. Both are reminders that the bone scan images bone turnover, not tumor directly, and that acquisition quality—symmetric positioning, adequate whole-body sweep counts, and consistent processing—is what makes these patterns legible. ¹²

Practical Optimization Tips

1. Match administered activity to the patient and the task

Use guideline activity as the anchor, scale for body habitus and pediatric weight, and keep activity within the facility's written-directive and diagnostic-reference-level framework. Lower activity means lower dose but demands adequate acquisition time to preserve counts. ²⁷

2. Protect the delayed-phase contrast

Encourage hydration and have the patient void immediately before delayed imaging. This clears soft-tissue and bladder background and improves lesion conspicuity without any change in equipment. ¹

3. Lock down collimator and window

Confirm the LEHR collimator is mounted and undamaged and that the photopeak window is correctly centered on 140 keV. A wrong window or a dinged collimator silently degrades every image of the day. ²

4. Specify count density, not just delay

Delay improves contrast but reduces activity; specify acquisition time or count targets for whole-body and SPECT so images remain statistically adequate. ¹

5. Use SPECT/CT for equivocal findings

Add SPECT/CT when a planar finding is indeterminate. The accuracy gain and reduction in equivocal reads are well documented, and the anatomic localization changes management. ⁶

6. Keep the camera and SPECT/CT in calibration

Daily uniformity/energy-peak checks, periodic center-of-rotation and SPECT/CT registration QC, and NEMA-based performance testing underpin every clinical image. See gamma camera NEMA NU-1 performance testing. ⁸⁹

Common pitfalls to avoid

• Under-counted delayed images. Adequate delay without adequate counts produces noisy, unreliable scans.
• Reading planar hot spots in isolation. Skipping SPECT/CT on equivocal lesions sacrifices specificity.
• Neglecting hydration/voiding. Retained soft-tissue and bladder activity masks pelvic and spinal lesions.
• Ignoring collimator and window QC. Small equipment faults degrade every study.
• Copying activity blindly. Administered activity should be tailored and documented, not defaulted.

Regulatory Considerations

Bone scintigraphy is a medical use of byproduct material, so it sits under NRC (or Agreement State) authority for the radioactive material and under professional practice standards for the imaging itself. ¹²

• 10 CFR Part 35 — Medical Use of Byproduct Material governs authorized use, the written directive framework where applicable, radiation safety, and the RSO's responsibilities for Tc-99m diphosphonate. Radioactive material is regulated by the NRC or an Agreement State; the imaging equipment and its physics performance follow professional and accreditation standards.
• EANM practice guidelines for bone scintigraphy and the SNMMI Procedure Standard for Bone Scintigraphy 4.0 define accepted acquisition, processing, and interpretation practice, including administered activity ranges, delay times, and collimator/window selection. ¹²
• ICRP Publication 128 provides the dose coefficients used to estimate patient effective dose and support optimization. ⁷
• NEMA NU 1 and IAEA quality-assurance guidance for SPECT systems define the camera and SPECT/CT performance-testing methodology that keeps clinical images reliable. ⁸⁹

Among the states DRPS serves, Florida, Maryland, Virginia, California, Nevada, Pennsylvania, New York, and New Jersey are NRC Agreement States that license medical use under their own radiation-control programs, while Washington DC and Delaware are regulated directly by the NRC. A facility should confirm which authority issues its license and align its bone-scan program—activities, surveys, QC, and physicist support—with those requirements and with PET/CT and nuclear medicine physics oversight.

Frequently Asked Questions (FAQs)

What radiopharmaceutical is used for a bone scan?

The standard agent is technetium-99m labeled to a diphosphonate, most commonly methylene diphosphonate (Tc-99m MDP) or hydroxymethylene diphosphonate (Tc-99m HDP/HMDP). Tc-99m emits a 140 keV gamma photon well suited to the gamma camera and has a 6-hour physical half-life. The diphosphonate binds to bone mineral in proportion to osteoblastic activity and regional blood flow.

How does Tc-99m MDP localize in bone?

The diphosphonate undergoes chemisorption onto the hydroxyapatite crystal surface of bone mineral. Uptake is greatest where bone turnover and osteoblastic activity are high and where regional blood flow is increased, which is why fractures, metastases, infection, and arthritis appear as areas of increased tracer accumulation.

What is a three-phase bone scan?

A three-phase study acquires a dynamic flow phase (rapid frames during and just after injection), an immediate blood-pool (soft-tissue) phase, and a delayed phase 2 to 5 hours later. Comparing the three phases helps distinguish active processes such as osteomyelitis or acute fracture from more indolent findings, because infection and acute injury are typically hyperemic on the early phases.

How much activity is administered for a bone scan?

Guidelines describe a typical adult administered activity of roughly 740 to 1110 MBq (20 to 30 mCi) of Tc-99m diphosphonate, with adjustment for body habitus and pediatric weight-based scaling. The exact activity should follow the facility's written directive framework and local diagnostic reference levels.

Why is bone scan imaging delayed for several hours?

Delay allows the diphosphonate not bound to bone to clear from soft tissue and blood, chiefly through the kidneys. This raises the bone-to-background ratio and improves lesion conspicuity. Imaging is typically performed 2 to 5 hours after injection; adequate hydration and voiding before imaging further reduce background and bladder activity.

What does SPECT/CT add to a bone scan?

SPECT adds three-dimensional localization, and the fused CT provides anatomic correlation and attenuation context. Together they reduce equivocal reads by characterizing a planar hot spot as, for example, a facet joint, a healing rib, or a vertebral metastasis. Studies report higher diagnostic accuracy and fewer indeterminate lesions with SPECT/CT than with planar imaging or either modality alone.

What collimator and energy window are used?

Bone scintigraphy is performed with a low-energy high-resolution (LEHR) parallel-hole collimator and a photopeak energy window centered on 140 keV, commonly 15 to 20 percent wide. Correct collimator selection and window setting are routine QC items; a mismatched window or a damaged collimator degrades resolution and contrast.

Key Takeaways

• Physics drives the diagnosis. Chemisorption onto hydroxyapatite, a 140 keV photon, and a 6-hour half-life make Tc-99m diphosphonate the ideal skeletal agent.
• Delay buys contrast, not counts. Soft-tissue clearance raises target-to-background ratio; count density must be specified so delayed images stay statistically adequate.
• Three phases separate hyperemia from turnover. Flow and blood-pool phases carry the discriminating information for infection and acute injury.
• Dose scales with activity. At ~0.0057 mSv/MBq, a 740–1110 MBq study delivers roughly 4–6 mSv; lower activity is the main dose lever.
• SPECT/CT fixes specificity. Anatomic localization raises accuracy and cuts equivocal reads on indeterminate planar findings.
• QC underpins everything. Correct collimator and window, and calibrated camera/SPECT-CT performance, keep the study reliable.

Conclusion

The Tc-99m MDP bone scan endures because it does something few studies can: survey the entire skeleton's metabolic activity in one sensitive acquisition. But sensitivity without technique produces noisy, nonspecific images. The path to a reliable study runs through physics—appropriate activity and dose, adequate delay and hydration for contrast, sufficient counts for statistics, correct collimator and window, and SPECT/CT for the anatomic characterization that turns a hot spot into a diagnosis.

A facility that treats these as controlled, documented parameters—rather than defaults—delivers bone scans that are accurate, defensible, and optimized for patient dose. That is the difference between a study that is merely positive and one that answers the clinical question.

How DRPS Can Help

Diagnostic Radiation Physics Services supports nuclear medicine departments in building and maintaining reliable skeletal imaging programs. Our PET/CT and nuclear medicine physics services include gamma camera and SPECT/CT acceptance and annual performance testing, uniformity and center-of-rotation QC, SPECT/CT registration and calibration, protocol and administered-activity review, and dose optimization aligned with EANM, SNMMI, ICRP, and NEMA methodology. We also provide medical physicist consulting and accreditation support.

DRPS supports facilities across our service locations, including Florida, Maryland, Virginia, Washington DC, California, Nevada, New York, Pennsylvania, New Jersey, and Delaware.

A sensitive study deserves a program that keeps it specific and reliable.

Related Resources

• SPECT/CT quality control
• Gamma camera collimator selection
• Gamma camera NEMA NU-1 performance testing
• Quantitative SPECT/CT calibration
• Renal scintigraphy and split renal function
• PET/CT and nuclear medicine physics
• Medical physicist consulting

References

1. Van den Wyngaert T, Strobel K, Kampen WU, et al. The EANM practice guidelines for bone scintigraphy. Eur J Nucl Med Mol Imaging. 2016;43(9):1723-1738. doi:10.1007/s00259-016-3415-4. PubMed
2. Society of Nuclear Medicine and Molecular Imaging. SNMMI Procedure Standard for Bone Scintigraphy, Version 4.0. J Nucl Med Technol. 2018;46(4):398-404. snmjournals.org
3. Beheshti M, Mottaghy FM, Paycha F, et al. 18F-NaF PET/CT: EANM procedure guidelines for bone imaging. Eur J Nucl Med Mol Imaging. 2015;42(11):1767-1777. doi:10.1007/s00259-015-3138-y. PubMed
4. Graham R, Morland D, Cade S, et al. EANM position paper on challenges and opportunities of full-ring 360° CZT bone imaging. Eur J Nucl Med Mol Imaging. 2025;52(3):1200-1209. doi:10.1007/s00259-024-06906-4. PubMed
5. Dickson JC, Armstrong IS, Gabiña PM, et al. EANM practice guideline for quantitative SPECT-CT. Eur J Nucl Med Mol Imaging. 2023;50(4):980-995. doi:10.1007/s00259-022-06028-9. PubMed
6. Zhang Y, Li B, Shi H, Yu H, Gu Y, Xiu Y. Added value of SPECT/spiral CT versus SPECT or CT alone in diagnosing solitary skeletal lesions. Nuklearmedizin. 2017;56(4):139-145. doi:10.3413/Nukmed-0886-17-03. PubMed
7. International Commission on Radiological Protection. ICRP Publication 128: Radiation Dose to Patients from Radiopharmaceuticals — A Compendium of Current Information Related to Frequently Used Substances. Ann ICRP. 2015;44(2S). icrp.org
8. National Electrical Manufacturers Association. NEMA Standards Publication NU 1: Performance Measurements of Gamma Cameras. nema.org
9. International Atomic Energy Agency. Quality Assurance for SPECT Systems (IAEA Human Health Series No. 6). 2009. iaea.org
10. International Commission on Radiological Protection. ICRP Publication 103: The 2007 Recommendations of the International Commission on Radiological Protection. Ann ICRP. 2007;37(2-4). icrp.org